Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT02834416
Other study ID # 14-8158-CE
Secondary ID
Status Completed
Phase Phase 3
First received
Last updated
Start date August 2016
Est. completion date March 31, 2020

Study information

Verified date April 2021
Source University Health Network, Toronto
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

Prostate Cancer (PC) affects 1 in 7 men. Nearly half of those diagnosed with PC will receive androgen deprivation therapy (ADT) as part of their treatment. ADT is good at managing PC but has many side effects. Researchers have shown that exercise, specifically one-on-one supervised exercise improves many of the side effects of ADT. However, exercise programs for men on ADT are not widely available. More questions need to be answered in order for exercise programs to become part of PC treatment. First, can programs that require fewer resources, such as group-exercise or home-based exercise, also improve ADT side-effects? Second, do exercise-related benefits continue beyond the structured exercise program? And what makes people continue exercising? Third, which exercise program is most cost-effective? In this study, the investigators will compare: (a) group supervised in-centre and (b) home-based supported exercise programs to see which program is most effective for men with PC on ADT. The investigators will also look at what motivates people to continue to exercise both during a structured program and after the program is complete and will examine which exercise program is most cost-effective. Participants (men with PC on ADT) will be recruited from one of the following cancer centres: Princess Margaret Cancer Centre in Toronto, the Tom Baker Cancer Centre in Calgary, the Southlake Regional Health Centre in Newmarket, and Scarborough and Rouge Hospital - Centenary Site in Scarborough. When a patient agrees to participate, patient will be randomly placed in 1 of 2 exercise programs. All programs will include the same type of exercises (aerobic, resistance and flexibility) and all participants will exercise 4-5 days per week for 30 minutes per day (as tolerated) for the length of the program (6 months). The investigators will look at how men with PC on ADT respond to the exercise program by measuring quality of life (QOL), fatigue and different physical measures before, during, and after the exercise program. Although the investigators know that supervised one-on-one exercise is most effective at improving ADT side-effects, it is unknown if other forms of exercise are just as beneficial and more financially responsible. This study will allow the investigators to begin to answer these questions so that structured exercise programs become a regular part of PC treatment.


Recruitment information / eligibility

Status Completed
Enrollment 38
Est. completion date March 31, 2020
Est. primary completion date March 31, 2020
Accepts healthy volunteers No
Gender Male
Age group N/A and older
Eligibility Inclusion Criteria: - men with histologically confirmed PC who are starting or continuing on ADT for at least 6 months or who are in an androgen-deprived (or castrate) state for the duration of the intervention - fluent in English - able to provide consent - close to a study centre Exclusion Criteria: - already meeting guidelines for moderate to vigorous physical activity (MVPA) - conditions that would interfere with ability to participate

Study Design


Related Conditions & MeSH terms


Intervention

Behavioral:
Supervised Group Exercise
The exercise program will be delivered in a group format (4-8 participants per group) by a certified exercise specialist.
Home Based Exercise
The exercise program will be executed independently by participants in a home-based setting. Home-based participants will be supported with remote health coaching and smartphone technology.

Locations

Country Name City State
Canada University of Calgary/Tom Baker Cancer Centre Calgary Alberta
Canada Southlake Regional Health Centre Newmarket Ontario
Canada Princess Margaret Cancer Centre Toronto Ontario
Canada Scarborough and Rouge Hospital Toronto Ontario

Sponsors (4)

Lead Sponsor Collaborator
University Health Network, Toronto Scarborough Rouge Hospital, Southlake Regional Health Centre, Tom Baker Cancer Centre

Country where clinical trial is conducted

Canada, 

Outcome

Type Measure Description Time frame Safety issue
Primary Functional Assessment of Cancer Therapy-Fatigue (FACT-F) The FACT-F is a questionnaire that includes 13 items measuring cancer-related fatigue. Every 3 Months for 12 Months
Primary 6 Minute Walk Test (6MWT) The 6MWT is a commonly used, validated measure that assesses functional endurance. Every 3 Months for 12 Months
Secondary Functional Assessment of Cancer Therapy-General (FACT-G) The FACT-G is a questionnaire that is well-validated and widely used to measure quality of life (QOL). Every 3 Months for 12 Months
Secondary Functional Assessment of Cancer Therapy-Prostate (FACT-P) The FACT-P is a questionnaire that supplements the FACT-G with 12 prostate-specific items covering domains of urinary function, sexual function, pain, and related symptoms. Every 3 Months for 12 Months
Secondary 5 Times Sit to Stand Test A common, simple, and validated measure of functional lower body strength. Every 3 Months for 12 Months
Secondary Grip Strength Grip strength is a measure of upper body strength and predicts long-term disability and mortality in middle-aged and older adults. Every 3 Months for 12 Months
Secondary Bioelectrical Impedance Analysis Body composition will be measured using bioelectrical impedance analysis (BIA). Every 6 Months for 12 Months
Secondary Waist Circumference and Hip Ratio Body composition will be measured using waist circumference(WC) and WC:hip ratio, following the standardized Canadian Society for Exercise Physiology - Physical Activity Training for Health (CSEP-PATH) protocol. Every 6 Months for 12 Months
Secondary Body Mass Index Body composition will be measured using body mass index (BMI). Every 6 Months for 12 Months
Secondary Bone Mineral Density (BMD) Bone mineral density will be measured at lumbar spine, hip, and distal 1/3 radius using dual x-ray absorptiometry (DXA). Every 6 Months for 12 Months
Secondary Biological Outcomes (blood work) Fasting lipids, blood glucose, glycated hemoglobin, hemoglobin, prostate-specific antigen (PSA), and testosterone will be measured. Serum banking will also be done for use in future studies. Every 6 Months for 12 Months
Secondary Sedentary Behaviour Time spent in activities that are characterized by an energy expenditure = 1.5 metabolic equivalents and a sitting or reclining posture (sedentary behavior) will be assessed using the Sedentary Behaviour Questionnaire that is used in large cohort studies and has demonstrated evidence of reliability and validity. Every 6 Months for 12 Months (unless otherwise specified)
Secondary Planning, Attitudes, & Barriers scale The Planning, Attitudes, & Barriers scale is a validated questionnaire that will be used to assess likelihood of exercise behavior over time. Every 6 Months for 12 Months (unless otherwise specified)
Secondary Behavioral Regulations in Exercise Questionnaire-2 (BREQ-2) Behavioral Regulations in Exercise Questionnaire-2 (BREQ-2) is a validated questionnaire that assess predictors of adherence. Every 6 Months for 12 Months (unless otherwise specified)
Secondary Psychological Need Support and Frustration Scale - Relatedness Items Relatedness will be assessed using the Psychological Need Support and Frustration Scale - Relatedness Items. Every 6 Months for 12 Months (unless otherwise specified)
Secondary Health Care Climate Questionnaire (HCCQ) The Health Care Climate Questionnaire (HCCQ short form) assess participant perceptions of their health care team. Baseline only
Secondary Walkability Participant postal codes will be collected to assess neighbourhood walkability (i.e., access to a grocery store within walking distance). Baseline only
Secondary Disease-related Costs The investigators will collect economically relevant data about health status using preference-based (utility) instruments (European Quality of Life Five Dimensions Questionnaire, EQ-5D). Productivity losses and out-of-pocket expenditures, in addition to hospitalization, drug co-pay, and health visit data will be gathered using a patient questionnaire. Every 3 Months for 12 Months
Secondary Exercise Adherence Both accelerometry and the Godin Leisure Time Exercise Questionnaire will be used as a measure of adherence at each time point. Both measures will provide a validated measure of physical activity. Every 3 Months for 12 Months
See also
  Status Clinical Trial Phase
Recruiting NCT05613023 - A Trial of 5 Fraction Prostate SBRT Versus 5 Fraction Prostate and Pelvic Nodal SBRT Phase 3
Recruiting NCT05540392 - An Acupuncture Study for Prostate Cancer Survivors With Urinary Issues Phase 1/Phase 2
Recruiting NCT05156424 - A Comparison of Aerobic and Resistance Exercise to Counteract Treatment Side Effects in Men With Prostate Cancer Phase 1/Phase 2
Completed NCT03177759 - Living With Prostate Cancer (LPC)
Completed NCT01331083 - A Phase II Study of PX-866 in Patients With Recurrent or Metastatic Castration Resistant Prostate Cancer Phase 2
Recruiting NCT05540782 - A Study of Cognitive Health in Survivors of Prostate Cancer
Active, not recruiting NCT04742361 - Efficacy of [18F]PSMA-1007 PET/CT in Patients With Biochemial Recurrent Prostate Cancer Phase 3
Completed NCT04400656 - PROState Pathway Embedded Comparative Trial
Completed NCT02282644 - Individual Phenotype Analysis in Patients With Castration-Resistant Prostate Cancer With CellSearch® and Flow Cytometry N/A
Recruiting NCT06305832 - Salvage Radiotherapy Combined With Androgen Deprivation Therapy (ADT) With or Without Rezvilutamide in the Treatment of Biochemical Recurrence After Radical Prostatectomy for Prostate Cancer Phase 2
Recruiting NCT06037954 - A Study of Mental Health Care in People With Cancer N/A
Recruiting NCT05761093 - Patient and Physician Benefit/ Risk Preferences for Treatment of mPC in Hong Kong: a Discrete Choice Experiment
Completed NCT04838626 - Study of Diagnostic Performance of [18F]CTT1057 for PSMA-positive Tumors Detection Phase 2/Phase 3
Recruiting NCT03101176 - Multiparametric Ultrasound Imaging in Prostate Cancer N/A
Completed NCT03290417 - Correlative Analysis of the Genomics of Vitamin D and Omega-3 Fatty Acid Intake in Prostate Cancer N/A
Completed NCT00341939 - Retrospective Analysis of a Drug-Metabolizing Genotype in Cancer Patients and Correlation With Pharmacokinetic and Pharmacodynamics Data
Completed NCT01497925 - Ph 1 Trial of ADI-PEG 20 Plus Docetaxel in Solid Tumors With Emphasis on Prostate Cancer and Non-Small Cell Lung Cancer Phase 1
Recruiting NCT03679819 - Single-center Trial for the Validation of High-resolution Transrectal Ultrasound (Exact Imaging Scanner ExactVu) for the Detection of Prostate Cancer
Completed NCT03554317 - COMbination of Bipolar Androgen Therapy and Nivolumab Phase 2
Completed NCT03271502 - Effect of Anesthesia on Optic Nerve Sheath Diameter in Patients Undergoing Robot-assisted Laparoscopic Prostatectomy N/A